324 related articles for article (PubMed ID: 8096505)
1. Cellular models for multiple drug resistance in cancer.
Clynes M
In Vitro Cell Dev Biol; 1993 Mar; 29A(3 Pt 1):171-9. PubMed ID: 8096505
[No Abstract] [Full Text] [Related]
2. Antineoplastic drug resistance and breast cancer.
Morrow CS; Cowan KH
Ann N Y Acad Sci; 1993 Nov; 698():289-312. PubMed ID: 7904140
[No Abstract] [Full Text] [Related]
3. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias.
Gekeler V; Frese G; Noller A; Handgretinger R; Wilisch A; Schmidt H; Muller CP; Dopfer R; Klingebiel T; Diddens H
Br J Cancer; 1992 Sep; 66(3):507-17. PubMed ID: 1355660
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of multidrug resistance.
Bradley G; Juranka PF; Ling V
Biochim Biophys Acta; 1988 Aug; 948(1):87-128. PubMed ID: 2899442
[No Abstract] [Full Text] [Related]
5. Multidrug resistance in cancer.
Ferry DR; Kerr DJ
BMJ; 1994 Jan; 308(6922):148-9. PubMed ID: 7906169
[No Abstract] [Full Text] [Related]
6. Clinical significance of P-glycoprotein in multidrug resistance malignancies.
Arceci RJ
Blood; 1993 May; 81(9):2215-22. PubMed ID: 8097632
[No Abstract] [Full Text] [Related]
7. Cellular resistance to drugs.
Krishan A
Cancer Invest; 1989; 7(2):211-2. PubMed ID: 2571401
[No Abstract] [Full Text] [Related]
8. Multidrug resistance (mdr) genes in human cancer.
Nooter K; Herweijer H
Br J Cancer; 1991 May; 63(5):663-9. PubMed ID: 1674875
[No Abstract] [Full Text] [Related]
9. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Volm M; Kästel M; Mattern J; Efferth T
Cancer; 1993 Jun; 71(12):3981-7. PubMed ID: 8099529
[TBL] [Abstract][Full Text] [Related]
10. The clinical relevance of multidrug resistance.
Bellamy WT; Dalton WS; Dorr RT
Cancer Invest; 1990; 8(5):547-62. PubMed ID: 1979932
[No Abstract] [Full Text] [Related]
11. Genetic aspects of multidrug resistance.
Pauly M; Ries F; Dicato M
Med Oncol Tumor Pharmacother; 1992; 9(1):21-4. PubMed ID: 1364127
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance and P-glycoprotein expression in human cancer.
Ma DD; Bell DR
Aust N Z J Med; 1989 Dec; 19(6):736-43. PubMed ID: 2576624
[No Abstract] [Full Text] [Related]
13. Glutathione-related enzymes, glutathione and multidrug resistance.
Moscow JA; Dixon KH
Cytotechnology; 1993; 12(1-3):155-70. PubMed ID: 7765324
[TBL] [Abstract][Full Text] [Related]
14. P glycoprotein (P-gp) and drug resistance--time for reappraisal?
Kaye SB
Br J Cancer; 1993 Apr; 67(4):641-3. PubMed ID: 8097103
[No Abstract] [Full Text] [Related]
15. Liposomal delivery of antisense oligodeoxynucleotides. Application to the inhibition of the multidrug resistance in cancer cells.
Thierry AR; Dritschilo A
Ann N Y Acad Sci; 1992 Oct; 660():300-2. PubMed ID: 1364094
[No Abstract] [Full Text] [Related]
16. Multidrug resistance genes, p-glycoprotein and the liver.
Arias IM
Hepatology; 1990 Jul; 12(1):159-65. PubMed ID: 1973680
[No Abstract] [Full Text] [Related]
17. Genetic basis of multidrug resistance of tumor cells.
Kane SE; Pastan I; Gottesman MM
J Bioenerg Biomembr; 1990 Aug; 22(4):593-618. PubMed ID: 1977744
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein and multidrug resistance.
Skubitz KM
Am J Clin Pathol; 1990 Jan; 93(1):156-7. PubMed ID: 1967202
[No Abstract] [Full Text] [Related]
19. Laboratory aspects of multidrug resistance.
Fuqua SA; Merkel DE; McGuire WL
Cancer Treat Res; 1989; 42():45-59. PubMed ID: 2577107
[No Abstract] [Full Text] [Related]
20. Multidrug resistance: clinical findings and implications.
Friedlander ML; Bell DR
Cancer Treat Res; 1989; 42():63-77. PubMed ID: 2577108
[No Abstract] [Full Text] [Related]
[Next] [New Search]
